Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

priority access

- PMLiVE

The journey to market access 5.0

Few in pharma are unaware of the importance of delivering demonstrable value in collaboration with payers. But are we serious about patient outcomes?

- PMLiVE

AstraZeneca drops Palatin’s obesity drug after trial subject suffers allergic reaction

But collaboration with the US biotech remains in place

- PMLiVE

Merck KGaA acquires cancer drug from Symphogen

Will pay up to €495m for investigational metastatic colorectal cancer treatment

- PMLiVE

Market access webinar series begins with UK healthcare changes

Experts convene for first Sudler & Hennessey and Kantar Health online event

Novartis building

FDA panel backs Novartis’ updated cystic fibrosis drug

New version of inhaled tobramycin therapy is simpler to use

Novartis building

Novartis showcases COPD candidates at ERS meeting

Positive results for three late-stage drugs

- PMLiVE

Merck KGaA plans to cut 1,100 jobs in Germany

Production also halted at two German facilities

- PMLiVE

Merck Serono spins off biomarker specialist

Led by Jérôme Wojcik, Quartz Bio will operate as a contract research organisation

Novartis reaffirms commitment to UK respiratory research site

Will slim down and redevelop Horsham facility

- PMLiVE

Novartis eye drug Jetrea effective in phase III

Pharma company and its partner ThromboGenics report positive trial data

- PMLiVE

Astellas Pharma Europe appoint new senior director, market access

Dr Susan Wood was previously senior brand director of the company’s pain management franchise 

AstraZeneca and BGT shelve experimental sepsis drug

Decision follows CytoFab’s poor mid-stage clinical trial results

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links